Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48‐h infusion of fluorouracil/leucovorin for advanced pancreatic cancer

Chang, Hui-Wen; Wang, Chuan Cheng; Cheng, Ann Lii; Hsu, Chiun; Lu, Yen‐Shen; Chang, Ming Chu; Lin, Jaw Town; Wang, Hsiu Po; Shiah, Her Shyong; Liu, Tsang Wu; Chang, Jang Yang; Whang‐Peng, Jacqueline; Chen, Li Tzong

doi:10.1111/j.1440-1746.2005.04022.x

Cited by 8 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oxaliplatin's accumulative neurotoxicity and dose-limiting characteristics may lead to poor long-term quality of life for patients ( 23 , 24 ). When the cumulative dose of oxaliplatin is up to 800 mg/m 2 , the risk of persistent symptoms will be up to 15%, and persistent neuropathy symptoms may worsen patients' quality of life ( 25 ). Irinotecan is a cycle-specific tumor treatment drug that acts in the S phase ( 26 ).…”

Section: Discussionmentioning

confidence: 99%

Fluorouracil Supplemented With Oxaliplatin or Irinotecan for Solid Tumors: Indications From Clinical Characteristics and Health Outcomes of Patients

Zhao

Hong

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Fluorouracil combined with oxaliplatin (FOLFOX) and fluorouracil combined with irinotecan (FOLFIRI) are both first-line clinical chemotherapy regimens. However, clinicians' selection of FOLFIRI or FOLFOX medication regimens and their effects on patients' health outcomes are not clear. The aim of this study was to evaluate the impacts on patient characteristics of FOLFIRI or FOLFOX medication regimen selection and the effects of each regimen on patients' health outcomes in a real-world setting. Three thousand seven hundred and twenty-five patients were retrieved and 610 of them were eventually included in this study based on the inclusion and exclusion criteria. The percentages of the TNM stage, cetuximab, bevacizumab, and tumor metastases between the FOLFIRI and FOLFOX groups were different ( P < 0.001). In the multivariate Cox proportional hazards model, a significantly higher non-convalescent incidence of the FOLFOX group was found as compared with the FOLFIRI group (HR = 2.211, 95% CI = 1.257–3.888, P = 0.006). In conclusion, the TNM stage, whether combined with cetuximab or bevacizumab, and whether there was tumor metastasis presented as the key factors affecting medication selection between the FOLFIRI and FOLFOX regimens. The FOLFIRI regimen exhibited better effects on patients' long-term health outcomes than did the FOLFOX regimen. This study was registered on the World Health Organization International Clinical Trials Registry Platform (ChiCTR2000029201). Trial registration: ChiCTR2000029201.

show abstract

Section: Discussionmentioning

confidence: 99%